IN2012MN02262A - - Google Patents

Download PDF

Info

Publication number: IN2012MN02262A
Authority: IN; India
Prior art keywords: multimeric protein; disclosed; protein structures; alpha; terms
Prior art date: 2010-03-02

Application number

Other languages

English (en)

Inventor

Avidor Shulman

Ilya Ruderfer

Tehila Ben-Moshe

Talia Shekhter

Yaniv Azulay

Yoseph Shaaltiel

Tali Kizhner

Original Assignee

Protalix Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-02

Filing date

2011-03-02

Publication date

2015-06-12

2010-11-17 Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/fr

2011-03-02 Application filed by Protalix Ltd filed Critical Protalix Ltd

2015-06-12 Publication of IN2012MN02262A publication Critical patent/IN2012MN02262A/en

Links

102000004169 proteins and genes Human genes 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
208000024720 Fabry Disease Diseases 0.000 abstract 1
102000005840 alpha-Galactosidase Human genes 0.000 abstract 1
108010030291 alpha-Galactosidase Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002045 lasting effect Effects 0.000 abstract 1
125000005647 linker group Chemical group 0.000 abstract 1
230000002132 lysosomal effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000178 monomer Substances 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)

IN2262MUN2012 2010-03-02 2011-03-02 IN2012MN02262A (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US30948710P	2010-03-02	2010-03-02
PCT/IL2010/000956 WO2011061736A1 (fr)	2009-11-17	2010-11-17	Alpha galactosidase alcaline pour le traitement de la maladie de fabry
US201161434499P	2011-01-20	2011-01-20
US201161434503P	2011-01-20	2011-01-20
PCT/IL2011/000209 WO2011107990A1 (fr)	2010-03-02	2011-03-02	Alpha-galactosidase stabilisée et ses applications

Publications (1)

Publication Number	Publication Date
IN2012MN02262A true IN2012MN02262A (fr)	2015-06-12

Family

ID=44121635

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2262MUN2012 IN2012MN02262A (fr)	2010-03-02	2011-03-02

Country Status (23)

Country	Link
EP (3)	EP2865751B1 (fr)
JP (2)	JP5758920B2 (fr)
KR (1)	KR101928403B1 (fr)
CN (1)	CN102933707B (fr)
AU (1)	AU2011222452B2 (fr)
BR (2)	BR122014021216A2 (fr)
CA (1)	CA2791461C (fr)
DK (1)	DK2865751T3 (fr)
ES (2)	ES2606532T3 (fr)
FI (1)	FIC20230032I1 (fr)
FR (1)	FR23C1041I2 (fr)
HR (1)	HRP20200428T1 (fr)
HU (2)	HUE030959T2 (fr)
IL (2)	IL221741A (fr)
IN (1)	IN2012MN02262A (fr)
NL (1)	NL301249I2 (fr)
NO (1)	NO2023041I1 (fr)
NZ (2)	NZ623294A (fr)
PL (1)	PL2865751T3 (fr)
SG (2)	SG183558A1 (fr)
SI (1)	SI2865751T1 (fr)
WO (1)	WO2011107990A1 (fr)
ZA (1)	ZA201206725B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9194011B2 (en)	2009-11-17	2015-11-24	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
SI2865751T1 (sl) *	2010-03-02	2017-01-31	Protalix Ltd.	Stabilizirana alfa-galaktozidaza in njene uporabe
KR101883803B1 (ko) *	2011-01-20	2018-07-31	프로탈릭스 리미티드	식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
TWI793159B (zh) *	2013-10-23	2023-02-21	美商健臻公司	重組醣蛋白及其用途
LT3237621T (lt) *	2014-12-22	2023-09-25	Codexis, Inc.	Žmogaus alfa-galaktozidazės variantai
WO2016116966A1 (fr) *	2015-01-22	2016-07-28	Jcr Pharmaceuticals Co., Ltd.	Procédé de purification d'une alpha-galactosidase a recombinante humaine à partir de matériel contenant des protéines contaminantes des cellules hôtes
WO2016146760A1 (fr)	2015-03-17	2016-09-22	Greenovation Biotech Gmbh	Protéines lysosomales glycosylées, procédé de production et utilisations
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
WO2018127920A1 (fr) *	2017-01-05	2018-07-12	Protalix Ltd.	Régime thérapeutique pour le traitement de la maladie de fabry à l'aide d'une alpha-galactosidase stabilisée
US11517613B2 (en) *	2017-06-07	2022-12-06	Amano Enzyme Inc.	Lactase bulk powder and lactase preparation
AU2019403323B2 (en)	2018-12-20	2026-02-26	Codexis, Inc.	Human alpha-galactosidase variants
CA3173294A1 (fr) *	2020-02-28	2021-09-02	Codexis, Inc.	Variants d'alpha-galactosidase humaine
MX2023005235A (es)	2020-11-03	2023-10-16	Protalix Ltd	Uricasa modificada y usos de la misma.
CN112176026A (zh) *	2020-11-06	2021-01-05	诺道中科(北京)生物科技有限公司	一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) *	2022-11-24	2024-06-04	西北农林科技大学	玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) *	2024-04-24	2025-01-24	武汉简为医疗科技有限公司	一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja)	2024-06-21	2025-09-26	デンカ株式会社	目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5766897A (en)	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US5401650A (en)	1990-10-24	1995-03-28	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (fr)	1991-10-03	1993-04-04	Guy Ampleman	Polymere de glycidylazide
US6329191B1 (en) *	1993-08-30	2001-12-11	Hawaii Biotechnology Group, Inc.	DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) *	1996-09-26	2005-02-10	Metabogal Ltd.	Cell/tissue culturing device, system and method
DE69839563D1 (de) *	1997-09-05	2008-07-10	Altus Pharmaceuticals Inc	Kohlenhydrat-vernetzte glykoproteinkristalle
IL125423A (en)	1998-07-20	2004-08-31	Israel State	Alkaline alpha-galactosidase having broad substrate specificity
DE60022336T2 (de) *	1999-04-02	2006-06-22	Ajinomoto Co., Inc.	Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
DK1523548T3 (da)	2002-05-15	2010-05-10	Agricultural Res Org	Polynukleotidsekvenser, som koder for alkaliske alfa-galactosidaser, og fremgangsmåder til anvendelse heraf
US7951557B2 (en) *	2003-04-27	2011-05-31	Protalix Ltd.	Human lysosomal proteins from plant cell culture
EP1877099B1 (fr) *	2005-04-06	2012-09-19	Genzyme Corporation	Conjugués thérapeutiques comprenant une enzyme lysosomale, l'acide polysialique et un agent de ciblage
BRPI0618583A2 (pt) *	2005-11-18	2011-09-06	Tokyo Metropolitan Org Med Res	enzima altamente funcional tendo especifidade ao substrato modificada
WO2008075957A1 (fr)	2006-12-21	2008-06-26	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Traitement de la maladie de fabry
JP2008169195A (ja) *	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (fr) *	2007-02-09	2008-08-13	Scil proteins GmbH	Conjugué multimère
CA2696699A1 (fr)	2007-08-20	2009-02-26	Protalix Ltd.	Conjugues de proteines contenant un saccharide et leurs utilisations
SI2865751T1 (sl) *	2010-03-02	2017-01-31	Protalix Ltd.	Stabilizirana alfa-galaktozidaza in njene uporabe

2011
- 2011-03-02 SI SI201131048A patent/SI2865751T1/sl unknown
- 2011-03-02 SG SG2012064580A patent/SG183558A1/en unknown
- 2011-03-02 IN IN2262MUN2012 patent/IN2012MN02262A/en unknown
- 2011-03-02 ES ES14195875.1T patent/ES2606532T3/es active Active
- 2011-03-02 NZ NZ623294A patent/NZ623294A/en unknown
- 2011-03-02 KR KR1020127025725A patent/KR101928403B1/ko active Active
- 2011-03-02 DK DK14195875.1T patent/DK2865751T3/en active
- 2011-03-02 PL PL14195875T patent/PL2865751T3/pl unknown
- 2011-03-02 EP EP14195875.1A patent/EP2865751B1/fr active Active
- 2011-03-02 EP EP16173953.7A patent/EP3088514B1/fr active Active
- 2011-03-02 ES ES16173953T patent/ES2708843T3/es active Active
- 2011-03-02 BR BR122014021216-0A patent/BR122014021216A2/pt active IP Right Grant
- 2011-03-02 AU AU2011222452A patent/AU2011222452B2/en active Active
- 2011-03-02 HU HUE14195875A patent/HUE030959T2/en unknown
- 2011-03-02 BR BR112012022029-2A patent/BR112012022029B1/pt active IP Right Grant
- 2011-03-02 CA CA2791461A patent/CA2791461C/fr active Active
- 2011-03-02 CN CN201180022145.6A patent/CN102933707B/zh active Active
- 2011-03-02 WO PCT/IL2011/000209 patent/WO2011107990A1/fr not_active Ceased
- 2011-03-02 SG SG10201502609QA patent/SG10201502609QA/en unknown
- 2011-03-02 NZ NZ602317A patent/NZ602317A/en unknown
- 2011-03-02 JP JP2012555542A patent/JP5758920B2/ja active Active
- 2011-03-02 EP EP11712340.6A patent/EP2542675B1/fr active Active
2012
- 2012-09-02 IL IL221741A patent/IL221741A/en active IP Right Grant
- 2012-09-07 ZA ZA2012/06725A patent/ZA201206725B/en unknown
2014
- 2014-08-06 JP JP2014160449A patent/JP5871999B2/ja active Active
2017
- 2017-06-29 IL IL253249A patent/IL253249B/en active IP Right Grant
2020
- 2020-03-16 HR HRP20200428TT patent/HRP20200428T1/hr unknown
2023
- 2023-10-31 HU HUS2300038C patent/HUS2300038I1/hu unknown
- 2023-11-01 NO NO2023041C patent/NO2023041I1/no unknown
- 2023-11-01 NL NL301249C patent/NL301249I2/nl unknown
- 2023-11-02 FR FR23C1041C patent/FR23C1041I2/fr active Active
- 2023-11-02 FI FIC20230032C patent/FIC20230032I1/fi unknown

Also Published As

Publication number	Publication date
HRP20200428T1 (hr)	2020-06-12
CN102933707B (zh)	2015-09-30
WO2011107990A1 (fr)	2011-09-09
JP5758920B2 (ja)	2015-08-05
FR23C1041I1 (fr)	2023-12-29
FR23C1041I2 (fr)	2024-08-02
SG183558A1 (en)	2012-10-30
BR112012022029B1 (pt)	2022-10-11
HUS2300038I1 (hu)	2023-11-28
DK2865751T3 (en)	2017-01-09
CA2791461A1 (fr)	2011-09-09
KR20130056216A (ko)	2013-05-29
RU2012141651A (ru)	2014-04-10
NL301249I2 (nl)	2023-12-14
ES2708843T3 (es)	2019-04-11
JP2013520986A (ja)	2013-06-10
SI2865751T1 (sl)	2017-01-31
BR112012022029A2 (pt)	2021-05-18
FIC20230032I1 (fi)	2023-11-02
IL253249A (en)	2019-08-29
SG10201502609QA (en)	2015-05-28
BR122014021216A2 (pt)	2021-06-01
JP2014237694A (ja)	2014-12-18
HUE030959T2 (en)	2017-06-28
ES2606532T3 (es)	2017-03-24
CN102933707A (zh)	2013-02-13
IL253249B (en)	2020-08-31
PL2865751T3 (pl)	2017-03-31
HK1180720A1 (en)	2013-10-25
JP5871999B2 (ja)	2016-03-01
EP2865751B1 (fr)	2016-09-14
AU2011222452A1 (en)	2012-09-27
EP3088514A1 (fr)	2016-11-02
NZ623294A (en)	2015-10-30
IL221741A (en)	2017-07-31
NO2023041I1 (no)	2023-11-01
EP3088514B1 (fr)	2018-11-28
EP2865751A1 (fr)	2015-04-29
CA2791461C (fr)	2019-10-22
NL301249I1 (fr)	2023-11-08
RU2604795C2 (ru)	2016-12-10
ZA201206725B (en)	2013-06-26
AU2011222452B2 (en)	2015-09-03
NZ602317A (en)	2014-04-30
EP2542675A1 (fr)	2013-01-09
EP2542675B1 (fr)	2014-12-17
KR101928403B1 (ko)	2018-12-14

Publication	Publication Date	Title
IN2012MN02262A (fr)	2015-06-12
WO2011027222A3 (fr)	2011-05-05	Compositions immunogènes comprenant des modulateurs de l'activité tlr
WO2012075040A3 (fr)	2014-04-10	Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
EP4253395A3 (fr)	2023-11-29	Procédés de préparation d'agents arn conjugués à des carbohydrates
WO2012129112A3 (fr)	2013-01-10	Utilisation d'enzymes intracellulaires pour libérer des produits bioactifs liés par covalence
WO2012077950A3 (fr)	2012-08-23	Conjugué acide hyaluronique-protéine et son procédé de préparation
MX2012002654A (es)	2012-03-26	Compuestos y composiciones como moduladores de la actividad de tlr.
MX350200B (es)	2017-08-30	Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2013013013A3 (fr)	2014-05-08	Compositions et procédés de production de glycoprotéines modifiées
WO2012099805A3 (fr)	2013-01-24	Stimulation immunologique à base de nanoparticules
MY161127A (en)	2017-04-14	Enhanced soluble c5 saccharide yields
PH12015500243A1 (en)	2015-03-30	Glycoconjugation processes and compositions
JO3065B1 (ar)	2017-03-15	مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011146518A3 (fr)	2012-03-08	Peptide c pégylé
IN2012DN02645A (fr)	2015-09-11
AU2011274619A8 (en)	2013-07-11	miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
HK1216850A1 (zh)	2016-12-09	抗ntb-a抗體及相關的組合物和方法
BR112014024282A2 (pt)	2017-08-08	anticorpos ligantes ao receptor b1 da bradicinina
WO2009135165A3 (fr)	2009-12-30	Petits peptides de type humanine
MX2017001898A (es)	2017-04-11	Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.
MX2012010448A (es)	2012-12-05	Conjugados de carbohidrato-poli aminoacido-farmaco.
WO2012064709A3 (fr)	2012-08-02	Protéines bêta-glucocérébrosidase recombinantes, variantes, ayant une stabilité accrue et une activité catalytique résiduelle accrue
WO2011112566A3 (fr)	2011-10-27	Protéines de liaison de basigine
PH12013500143A1 (en)	2019-09-02	A method of treating alzheimer`s disease
WO2012004013A3 (fr)	2012-04-26	Protéine transportrice de glucosinolate et ses utilisations